Hormonal
Adding liraglutide (1.2 or 1.8 mg/day) to maximized metformin and thiazolidinedione (TZD) therapy significantly improves glycemic control (A1C, fasting, and postprandial glucose) and induces dose-dependent weight loss in patients with type 2 diabetes.
If you have Type 2 Diabetes and are already taking metformin and a TZD (like rosiglitazone) but your blood sugar isn't controlled, adding liraglutide (1.2 or 1.8 mg once daily) can significantly lower your A1C and help you lose weight. While you might experience some nausea or stomach issues, these are usually temporary and happen mostly in the first few weeks. This combination is effective for improving blood sugar without causing major low blood sugar episodes.
Liraglutide combined with metformin and a thiazolidinedione is a well-tolerated combination therapy for type 2 diabetes, providing significant improvements in glycemic control.
Why this rating
Large-scale (n=533), double-blind, placebo-controlled, randomized parallel-group trial.
Source
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al. · Diabetes Care · 2009
DOI 10.2337/dc08-2124
More from this paper
- Liraglutide treatment in combination with metformin and TZD leads to significant reductions in systolic blood pressure and favorable changes in lipid profiles (specifically free fatty acids, LDL, and triglycerides) compared to placebo.Strong
- Liraglutide treatment improves beta-cell function (measured by C-peptide and HOMA-B) and reduces the proinsulin-to-insulin ratio compared to placebo when added to metformin and TZD.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →